Keros Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Keros Therapeutics, Inc. (KROS) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $5.12 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-04
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5.12M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.94M.
- 2024-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7.42M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.92M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $5.12M 10-K · filed 2026-03-04 |
| 2024-12-31 | $6.94M 10-K · filed 2025-02-26 |
| 2024-09-30 | $7.42M 10-Q · filed 2024-11-06 |
| 2023-12-31 | $6.92M 10-K · filed 2024-02-28 |
| 2023-09-30 | $7.29M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $7.65M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $8.01M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $6.91M 10-K · filed 2023-03-03 |
| 2021-12-31 | $54.00K 10-K · filed 2022-03-09 |
| 2021-09-30 | $76.00K 10-Q · filed 2021-11-04 |
| 2020-12-31 | $80.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |